The leading fully integrated biologics & bioconjugates (ADCs, AOCs, RDCs) CDMO+CRO

Abzena San Diego

Move your program forward to patients faster with Abzena's end-to-end, fully integrated expertise across cell line development, bioconjugation, process development & GMP manufacturing.

Why Abzena? GMP-Ready Cell Line Development

Let’s work together to keep moving medicine forward.

1400+ Lead Candidates Discovered & Designed - Abzena

1400+

Lead Candidates Discovered & Designed

100+ Production Cell Lines Developed - Abzena

100+

Production Cell Lines Developed

2000+ Bioconjugates Developed & 400+ ADCs Produced - Abzena

2000+

Bioconjugates Developed & 400+ ADCs Produced

 

Discover Our 20+ Years’ Scientific Expertise & Track Record

About Abzena

We enable you to bring life-changing treatments to patients in need with greater success. Leverage our extensive experience in complex biologics and bioconjugate development to rapidly move your idea forward.

Contact Us

Our Offering

Integrated Biologics

Accelerate your path to market with our advanced, integrated biologics CDMO + CRO services & solutions that move medicine forward.

Learn More

Bioconjugates (ADCs, AOCs, RDCs)

Accelerate your timeline to the clinic or the market with our expertise in complex chemistry and bioconjugation services.

Learn More

Complex Chemistry

We develop novel and improve synthetic routes for complex chemicals, cytotoxins, payloads, linkers, HPAPI and more.

Learn More

Moving Medicine Forward

We offer best-in-class, discovery through commercial bioconjugate and biologic CDMO + CRO services. Along with a highly detailed and personalized experience, when you partner with Abzena expect:

  • Access to Genuine Scientific & Technical Experts
  • Proactive Solutions for Streamlining Development
  • Diverse and Interconnected Teams
  • End-to-End Support Under One Organization

Abzena develops and implements fully integrated and tailored solutions that realize the full potential of your molecule. Our offering means that your bioconjugate or biologic programs can go from promise to product faster by providing:

  • Fully integrated early R&D through commercial capabilities
  • High-quality & trusted data that drives development
  • Streamlined regulatory support tailored to your program
Why Abzena?

We are advocates and partners for your success. We deploy the best biologic development technologies, shorten lead times, and implement effective risk mitigation strategies so that your focus can be on improving patient lives.

Discover Testimonials
“Throughout the development of AGX101, Abzena has worked closely with us to achieve successful GMP manufacturing and quality control. We could not have reached this milestone without Abzena’s expertise, cooperation, and support.”


Paul Jaminet

Paul Jaminet | Co-founder & CEO
Angiex

Explore customer testimonials
"Abzena has been crucial in advancing and validating our technology and programs. The team is very thoughtful, has strong troubleshooting skills and maintains a high standard in generating quality data with integrity. We highly recommend working with Abzena."

Shiva Bhowmik, PhD

Shiva Bhowmik, PhD | COO
TRIO Pharmaceuticals, Inc.

Explore customer testimonials
"We worked with the Abzena team for the design and the initial production of both the mAb and the antibody-chelator conjugate to support our R&D programs. We had a productive and valuable interaction with a highly skilled scientific team and we benefited from the flexibility of the services at this early stage of development."
Tina Bjørnlund Bønsdorff

Tina Bjørnlund Bønsdorff | CSO
Oncoinvent AS

Explore customer testimonials
"I’ve never had a CRO project go this smoothly and the ADCs delivered were very high quality. I’m confident that my client will put Abzena at the top of their list for future ADC projects."



David Jackson

David Jackson | Pharmaceutical Consultant & ADC Expert
DYJ Pharma Consulting

Explore customer testimonials

Latest Insights

News: Abzena Enhances AbZelectPRO™ Cell Line Offering with New GS Knockout Platforms

Announcing the expansion of our AbZelectPRO™ CLD platform with two next-gen GS knockout CHO-K1 expression systems, including ADCC+.

Learn More

Whitepaper: Random Integration vs. Semi-Targeted Integration in Stable Cell Line Development

Abzena's CLD experts explore two primary approaches - random integration and semi-targeted (or transposase) integration.

Learn More

Info Sheet: Robust & Flexible Cell Lines That Fit Your Strategy

AbZelectPRO™-KO & AbZelectPRO™-KO+, new CHOSOURCE™ GS knockout platforms are available as a standalone CLD offering or as a fully integrated GMP program.

Learn More

Upcoming Events

September 9th, 2026

PBSS Workshop: IND Filing & Nonclinical Considerations for Emerging Modalities

BMS, 250 Water St, East Cambridge, MA 02141
Read More

September 16th, 2026

TKS: Antibody-Drug Conjugates Symposium

Prague, Czech Republic
Read More

October 1st, 2026

PBSS Workshop: Preclinical Development and IND Filing for Antibody-Based Therapeutics

San Diego/Del Mar
Read More
Let’s move medicine forward - Abzena

Let's work together to move your medicine forward.

We enable you to bring life-changing medicines to patients in need faster.

Contact Us Download Brochure